At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,277,747 enrolled
Drug / intervention
BNT162b2 (Tozinameran)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Coronavirus Disease 2019 (COVID-19) Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
In Brief
An observational study evaluating BNT162b2 (Tozinameran) for Immunocompromised and 5 related conditions. Completed, enrolled 1,277,747 participants across 1 site.
Detailed Summary
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsImmunocompromised, Immunosuppressed, Covid-19, SARS-COV-2, SARS-COV-2 Infection, Breakthrough Infection
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedAug 25, 2021
Enrollment StartAug 25, 2021
Primary CompletionDec 17, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.9 years ago
Interventions
BNT162b2 (Tozinameran)biological
Covid-19 Vaccine